In addition, ACY1 expression levels were lower in patients with KRAS mutation but no lymph node metastasis (group B) than in group C. The expression levels were lowest in patients without lymph node metastasis and KRAS mutation (group A). This evidence concerns the gene ACY1 and metastatic malignant neoplasm in the lymph nodes.